Industry trends in orphan drug partnering – 2007 to 2013

In Partnering & Investment by Freya Smale1 Comment

Trends in orphan drugs partnering

Blogged on behalf of Current Partnering, Wildwood Ventures

Orphan drugs have become increasingly popular in the last decade, with 2011 seeing a fairly high frequency in deal making with 28 partnering deals. According to the Current Agreements life science deals and alliance database, there have been over 100 orphan drugs deals since 2007.

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease Unlike many other deal areas that involve top pharmaceutical (big pharma) companies taking part in deal making, orphan drugs has not been a popular area of deal making among the big pharma companies, with the exception of Pfizer. The reasons for this are pretty obvious in that big pharma prefer to seek out major therapeutic targets, in order to maximize return on R&D investment. However, this provides significant opportunity for smaller companies seeking a niche market opportunity.

Download this article to find out more about orphan drug dealmaking trends between 2007 and 2013  >

Comments

  1. guest

    Could each orphan drug R&D effort be managed in such a way that it could qualify as an investment entity open to appropriate investors? That might make it possible for certain individuals or groups with sufficient wealth to actively participate in advancing an orphan drug they have an interest in supporting.

Leave a Comment